読み込み中
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
終値時点
$10.36
+$0.03 · +0.29%
時間外
$10.36
$0.00 · 0.00%
10月9日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
日中レンジ
現在 $10.36
52週レンジ
現在 $10.36
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
81
大幅な割安
センチメント
68
強気
リスク
51
やや高いリスク
モメンタム
28
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
日中レンジ
現在 $10.36
52週レンジ
現在 $10.36
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 5.1億 USD | 4.26億 USD | 2.58億 USD | 1.54億 USD | 8094.3万 USD |
| 売上原価 | 2.17億 USD | 2.07億 USD | 1.69億 USD | 1.19億 USD | 7977万 USD |
| 粗利益 | 2.93億 USD | 2.2億 USD | 8894.2万 USD | 3526.5万 USD | 117.3万 USD |
| 研究開発 | 476.2万 USD | 181.3万 USD | 330万 USD | 361.4万 USD | 364.6万 USD |
| 販売・一般管理 | 9158万 USD | 7412.4万 USD | 5902万 USD | 5245.8万 USD | 4289.7万 USD |
| 営業費用 | 1.01億 USD | 8057万 USD | 6731万 USD | 7463万 USD | 5954.7万 USD |
| 受取利息 | 187.1万 USD | 209.7万 USD | 161.7万 USD | 4.48万 USD | 3.45万 USD |
| 支払利息 | 711万 USD | 1393万 USD | 2502.7万 USD | 1927.94万 USD | 1305.68万 USD |
| 減価償却費と償却費 | 809.6万 USD | 804.5万 USD | 833.2万 USD | 711.34万 USD | 549.55万 USD |
| 営業利益 | 1.91億 USD | 1.39億 USD | 2163.2万 USD | −3936.5万 USD | −5837.4万 USD |
| 純利益 | 1.47億 USD | 1.98億 USD | −2823.9万 USD | −6590.4万 USD | −7164.8万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$18.67
上昇余地（80.21%）この株式へのエクスポージャーを報告している上場投資信託です。
First Trust NYSE Arca Biotechnology Index FundFBT1.03億3.63%28.73億 USD0.55%$265.4+2.00%
Vanguard Morningstar Total Stock Market ETFVTI6612.07万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM6262.96万0.08%781.81億 USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI4859.44万0.48%101.08億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF2523.45万0.03%954億 USD0.05%$235+0.80%
Vanguard Morningstar Small-Cap ETFVB2377.42万0.01%1853億 USD0.03%$289.48+0.64%
iShares Russell 2000 Growth ETFIWO2203.4万0.16%140.44億 USD0.24%$356.78+0.94%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2118.14万0.13%158.02億 USD0.03%$53.45+0.17%First Trust NYSE Arca Biotechnology Index FundFBTVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 Growth ETFIWOState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
